Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease - Quiz - MDSpire

Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease

  • By

  • Vasantharaja Raguraman

  • Miranda Mysinger

  • Mohit Verma

  • Shanid Mohiyuddin

  • Nashwan Jabbour

  • Melissa Kesler

  • Trupti Joshi

  • Senthilnathan Palaniyandi

  • Gerhard C. Hildebrandt

  • June 11, 2026

  • 0 min

Share

Original Source(s)

Targeting Bruton tyrosine kinase with acalabrutinib attenuates murine sclerodermatous chronic graft versus host disease

  • by Vasantharaja Raguraman, Miranda Mysinger, Mohit Verma, Shanid Mohiyuddin, Nashwan Jabbour, Melissa Kesler, Trupti Joshi, Senthilnathan Palaniyandi, Gerhard C. Hildebrandt

  • June 11, 2026

Related Content

Building the Cell Therapy Ecosystem

Antoinette Gawin discusses leadership, innovation in blood and cell therapy, and the global systems shaping access to advanced medicine

  • June 8, 2026

  • 11 min
A diagnostic pitfall in iron-refractory microcytic hypochromic anemia with acquired ring sideroblasts initially treated as iron deficiency anemia—a case report

Soluble IL-2 receptor and memory Treg profiles differentiate early rheumatoid arthritis from undifferentiated arthritis at initial presentation